Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
Intellicheck
IDN
$56.7M
| $852K | ﹤0.01% |
113,759
+75,255
| +195% | +$467K |
|
|
WSTL
2702
DELISTED
Westell Technologies Inc
WSTL
| $852K | ﹤0.01% |
952,506
+20,400
| +2% | +$22.8K |
|
|
BGMS
2703
Bio Green Med Solution Inc
BGMS
$4.92M
| $850K | ﹤0.01% |
18
+2
| +13% | +$67K |
|
2704
Silicom
SILC
$282M
| $850K | ﹤0.01% |
25,558
+134
| +0.5% | +$4.33K |
|
2705
iShares Core 60/40 Balanced Allocation ETF
AOR
$3.74B
| $849K | ﹤0.01% |
17,754
+12,287
| +225% | +$575K |
|
2706
Matrix Service
MTRX
$331M
| $849K | ﹤0.01% |
37,100
-21,659
| -37% | -$428K |
|
|
TAIT
2707
DELISTED
Taitron Components
TAIT
| $849K | ﹤0.01% |
299,051
+11,500
| +4% | +$32.2K |
|
2708
Union Bankshares
UNB
$121M
| $848K | ﹤0.01% |
23,400
+2,400
| +11% | +$81.7K |
|
2709
MYR Group
MYRG
$5.23B
| $844K | ﹤0.01% |
+25,900
| New | +$855K |
|
|
CORE
2710
DELISTED
Core Mark Holding Co., Inc.
CORE
| $843K | ﹤0.01% |
31,000
-492,592
| -94% | -$13.6M |
|
2711
Virco
VIRC
$95.3M
| $839K | ﹤0.01% |
197,902
+6,302
| +3% | +$25.2K |
|
|
ATYR
2712
aTyr Pharma
ATYR
$54.8M
| $834K | ﹤0.01% |
199,920
+6,300
| +3% | +$24.3K |
|
|
CBAY
2713
DELISTED
Cymabay Therapeutics
CBAY
| $833K | ﹤0.01% |
424,840
+384,920
| +964% | +$1.45M |
|
2714
iShares MSCI South Korea ETF
EWY
$27.8B
| $827K | ﹤0.01% |
13,300
+4,100
| +45% | +$243K |
|
|
MOR
2715
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $826K | ﹤0.01% |
23,146
-5,354
| -19% | -$160K |
|
|
DVD
2716
DELISTED
Dover Motorsports
DVD
| $826K | ﹤0.01% |
444,146
+28,503
| +7% | +$54K |
|
2717
ProQR Therapeutics
PRQR
$258M
| $823K | ﹤0.01% |
83,000
-19,300
| -19% | -$150K |
|
2718
AXT Inc
AXTI
$5.24B
| $820K | ﹤0.01% |
188,500
+20,500
| +12% | +$65.8K |
|
|
NOVN
2719
DELISTED
Novan, Inc. Common Stock
NOVN
| $815K | ﹤0.01% |
25,797
+2,092
| +9% | +$49.1K |
|
|
ORKA
2720
Oruka Therapeutics
ORKA
$7.11B
| $814K | ﹤0.01% |
11,881
+3,540
| +42% | +$227K |
|
|
YMAB
2721
DELISTED
Y-mAbs Therapeutics
YMAB
| $813K | ﹤0.01% |
26,000
-44,700
| -63% | -$1.32M |
|
2722
PC Connection
CNXN
$2.05B
| $809K | ﹤0.01% |
16,300
-22,000
| -57% | -$1.02M |
|
|
HUSN
2723
DELISTED
Hudson Capital Inc. Ordinary Shares
HUSN
| $807K | ﹤0.01% |
327,966
+29,011
| +10% | +$71.9K |
|
|
THMO
2724
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
| $806K | ﹤0.01% |
4,072
+1,307
| +47% | +$252K |
|
2725
Vanguard Health Care ETF
VHT
$18.9B
| $805K | ﹤0.01% |
+4,200
| New | +$753K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.